The involvement of patient organisations in rare disease research: a mixed methods study in Australia by Pinto, Deirdre et al.
  
 
 
 
Pinto, Deirdre, Martin, Dominique and Chenhall, Richard 2016, The involvement of patient 
organisations in rare disease research: a mixed methods study in Australia, Orphanet journal of rare 
diseases, vol. 11, Article number: 2, pp. 1-15. 
 
DOI: 10.1186/s13023-016-0382-6 
 
 
 
 
 
 
 
This is the published version. 
 
 
©2016, The Authors 
 
Reproduced with the kind permission of the copyright owner. 
 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30083280 
 
 
 
 
RESEARCH Open Access
The involvement of patient organisations in
rare disease research: a mixed methods
study in Australia
Deirdre Pinto* , Dominique Martin and Richard Chenhall
Abstract
Background: We report here selected findings from a mixed-methods study investigating the role of Australian
rare disease patient organisations (RDPOs) in research. Despite there being many examples of RDPOs that have
initiated and supported significant scientific advances, there is little information – and none at all in Australia – about
RDPOs generally, and their research-related goals, activities, and experiences. This information is a pre-requisite for
understanding what RDPOs bring to research and how their involvement could be strengthened.
Methods: We reviewed 112 RDPO websites, conducted an online survey completed by 61 organisational
leaders, and interviewed ten leaders and two key informants. Quantitative and qualitative data were analysed
using basic descriptive statistics and content analysis, respectively.
Results: Although most are small volunteer-based groups, more than 90 % of the surveyed RDPOs had a
goal to promote or support research on the diseases affecting their members. Nearly all (95 %) had
undertaken at least one research-related activity – such as providing funding or other support to researchers
– in the previous five years. However, RDPO leaders reported considerable challenges in meeting their
research goals. Difficulties most frequently identified were insufficient RDPO resources, and a perceived lack of
researchers interested in studying their diseases. Other concerns included inadequate RDPO expertise in
governing research “investments”, and difficulty engaging researchers in the organisation’s knowledge and
ideas. We discuss these perceived challenges in the light of two systemic issues: the proliferation of and lack
of collaboration between RDPOs, and the lack of specific governmental policies and resources supporting rare
disease research and patient advocacy in Australia.
Conclusion: This study provides unique information about the experiences of RDPOs generally, rather than
experiences retrospectively reported by RDPOs associated with successful research. We describe RDPOs’
valuable contributions to research, while also providing insights into the difficulties for small organisations
trying to promote research. The study is relevant internationally because of what it tells us about RDPOs;
however, we draw attention to specific opportunities in Australia to support RDPOs’ involvement in research,
for the benefit of current and future generations affected by rare diseases.
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involvement, Consumer involvement
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Background
Each of the 6000 to 7000 rare diseases1 [1] affects
relatively few people, but collectively rare diseases
affect an estimated six to eight per cent of the popu-
lation [2]. Based on this estimate and Australia’s 23.7
million population at the end of 2014 [3], it is likely
that at least 1.4 million Australians have a rare dis-
ease. Because rare diseases are usually life-threatening
or chronically disabling, and most have no specific or
effective treatments [4, 5], they impact severely on affected
individuals and their families [6]. However, the low
prevalence of individual rare diseases means they have
historically received little attention from government
or industry research funders [4, 5, 7, 8].
In the absence of resources from other sources, support
from rare disease patient organisations (RDPOs) – defined
here as non-profit community groups representing people
affected by specific rare diseases – may be crucial to the
initiation and progress of biomedical research [9–11]. Like
patient organisations for more common diseases, RDPOs
emerged in the United States (US) around the middle of
the 20th century [10] and have since proliferated across
the Western world. While the traditional function of
RDPOs is to support patients and/or their families,
these organisations are believed to be playing increas-
ingly active roles in rare disease research [12–14]. In-
deed, there are now many examples of RDPOs that
have initiated and/or supported significant programs
of research [10, 13, 15–18], including the development of
new therapies for diseases such as cystic fibrosis [19, 20],
Pompe’s disease [21], Giant Axonal Neuropathy [13], and
lymphangiomyomatosis [22].
Internationally, there is growing interest in strength-
ening RDPOs’ engagement in research [14, 23, 24].
This trend is observed in the context of greater prioritisa-
tion of rare disease research by governments concerned
about the collective public health impacts of rare diseases
[5, 25, 26] and pharmaceutical companies attracted to rare
diseases as untapped markets [27]. RDPO-researcher
collaborations are also of interest to policy-makers re-
sponsible for promoting the involvement of patients and
their representatives in research [14, 28, 29], and to social
scientists concerned with how patient communities influ-
ence the directions, practices and cultures of biomedical
science [30, 31].
Despite the practical and theoretical significance of the
topic, there is limited information about how RDPOs are
involved in research. The relevant literature consists
mainly of case studies and reports of individual RDPOs
[9]. These accounts usually focus on organisations that
have successfully influenced research agendas and out-
comes, which may not be representative of RDPOs gener-
ally. While a few surveys [32–35] have examined the
research-related activities of larger numbers of RDPOs,
their authors provide limited information about RDPO
leaders’ experiences in supporting research. Under-
standing these experiences – including any challenges
or problems encountered by RDPOs that seek to advance
research – is an important underpinning for initiatives to
strengthen RDPOs’ contributions and collaborations with
researchers.
Australian context
As other authors have noted, previous studies of patient
organisations’ roles in research have been conducted
only in Europe and the US [30, 36]. In the absence of
studies or even descriptive reports of Australian RDPOs,
little is known about these organisations or their involve-
ment in rare disease research. The need for country-
specific information as a basis for policy development is
highlighted by evidence that the involvement of patient
organisations in research (for both rare and common
diseases) is influenced by the political and social context
in which the organisation is situated [30, 32, 36–38].
The environment for rare disease research and patient
advocacy is very different in Australia compared with
either Europe or the US. As discussed later in this
article, there are no specific policies or programs sup-
porting Australian rare disease research [38–41], with
the exception of “orphan drug” legislation providing
tax benefits and extended periods of market exclusivity for
pharmaceutical companies that develop drugs for rare and
neglected diseases [5, 42]. In contrast, Europe and the US
have significant government-funded programs and initia-
tives targeting rare disease research [5, 25, 43–45], includ-
ing a strong development program for infrastructure such
as registries and biobanks that can be used in the study of
any rare disease [27, 46, 47]. There are also major initia-
tives in both Europe and the US to strengthen RDPOs’
involvement in rare disease research and related delibera-
tive processes [23, 28, 34, 48–50].
Aim of our study
In this article, we report selected findings from a study
investigating the research-related goals, activities and
experiences of Australian RDPOs. In an effort to over-
come the limitations of previous studies, such as the lack
of representativeness of case studies and the restricted
depth of analysis possible in surveys, our study included
three different methods: an analysis of RDPO websites;
an online survey of Australian RDPO leaders; and in-
depth interviews with ten RDPO leaders and two key
informants.
We describe the characteristics of Australian RDPOs;
evaluate their research ambitions and modes of in-
volvement in research; and discuss the challenges that
Australian RDPO leaders identify with their efforts to
contribute to research. We consider this novel information
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in the context of current Australian research policies and
identify a number of specific opportunities to support
RDPOs’ involvement in research and their collaborations
with researchers, so as to capitalise more fully on their
potential contributions.
Methods
Identification of eligible RDPOs
RDPOs eligible for inclusion in this study were patient
organisations that focus on a disease, or closely related
set of diseases, with a community prevalence of 1 in
2000 or less. We also required that organisations met
the criteria for membership of the International Associ-
ation of Patient Organisations [51], and therefore included
only non-profit, non-government groups with a legal
status (such as incorporation) in Australia. Further, the
study was restricted to organisations with a website, as
this was necessary to check the organisation’s eligibility
for the study and collect contact details for the planned
online survey. Candidate organisations were initially iden-
tified from support groups listed on the websites of two
Australian rare disease alliance groups – Rare Voices
Australia [52] and the Association of Genetic Support
of Australasia (now Genetic Alliance Australia) [53] –
and from charities listed on the Australian Charities
and Not for Profits Register [54]. Further organisations
were identified using a snowballing method. We identified
117 eligible patient organisations.
Website screening and data extraction
All RDPO websites were screened during the initial
identification process (August to October 2013) to con-
firm eligibility for the study, collect contact details, and
inform the questions and code sets for the online survey.
At a later stage (January to March 2014) we analysed
the websites of 112 RDPOs (the other five websites
contained inadequate information or were not function-
ing in the analysis period). Website content was read in
its entirety – usually excluding any blogs and linked
documents or audio-visual material. Data on organisa-
tional characteristics, and stated research goals and
activities, if any, were recorded in a spreadsheet.
Survey
In late October and early November 2013, the leaders of
three RDPOs helped to pilot test a questionnaire. On 4
December 2013, the leaders of the remaining 114 RDPOs
were invited to participate in an online survey hosted by
an independent survey research company.
Respondents were asked to consider all aspects of
research on their diseases, from basic science studies
to the development and testing of diagnostic tools,
therapies and rehabilitative approaches, and research
investigating the impact of the disease on patients, families
or society. The questionnaire asked about RDPOs’ goals,
including research goals, and research-related activities in
the last five years. All respondents with a goal to support
research were asked how they would ideally like to
contribute to research, and what they considered the
barriers to their further involvement and to the pro-
gress of research on the disease. We also collected data
on organisational characteristics, such as age, number of
members and staff, funding sources, and budget.
By 8 March 2014, when the survey was closed, com-
pleted surveys were received from 61 RDPOs. The final
response rate of 53 % was achieved using one email
reminder and one telephone reminder. Survey respon-
dents and “non-responders”2 were compared according
to the age of their RDPOs, geographical coverage (state-
based, national etc.), disease prevalence, and whether or
not research goals were indicated on the organisation’s
website. No significant differences were found between
survey respondents and “non-responders” on any of the
variables examined.
Interviews
Survey recipients were asked to indicate their willingness
to be interviewed as part of the study. Ten RDPO
leaders who agreed were selected to participate in semi-
structured face-to-face interviews. Two key informants
were also interviewed in order to better understand the
broader context for rare disease patient organisations and
rare disease research in Australia. The key informants had
extensive experience in working with Australian RDPOs.
Data analysis
Due to the small size of the survey sample, the analysis
of quantitative survey data was limited to basic descrip-
tive statistics (frequency counts and percentages, cross-
tabulations, and correlations). These data were analysed
using the Statistical Package for the Social Sciences.
Qualitative information from answers to open-ended
survey questions and interviews was subject to content
analysis to identify key themes.
Ethics
The study was approved by The University of Melbourne’s
School of Population and Global Health Human Ethics
Advisory Group. Survey respondents had the option to
remain anonymous to the researchers, although most
chose to provide identifying information on the question-
naire. To protect their confidentiality, each study partici-
pant quoted in this article is referred to as a “survey
respondent” or – where interviewed – by a pseudonym.
Results
Our report of findings from our study of Australian
RDPOs begins with their basic characteristics (age;
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formation and governance; size and resources), followed
by the results of our survey question on key organisa-
tions goals. We then consider various research-related
activities conducted by RDPOs in the five years prior to
the survey. Finally, we present qualitative information,
from open-ended survey questions and interviews, about
the challenges identified by study participants when
asked about the impacts of and constraints on their
involvement in research.
Characteristics of Australian RDPOs
Age
Consistent with international trends [55], Australian
patient groups focused on rare diseases emerged in the
1950s. The oldest RDPOs – for people affected by two
of the more common rare diseases, muscular dystrophy
and cystic fibrosis – were up to sixty years old at the
time of the survey. However, most current RDPOs are
much younger. More than half the surveyed RDPOs had
been in existence less than 20 years, with about one
third less than a decade old (Fig. 1).
RDPOs aged ten years or less at time of the survey
differed from older groups in a number of respects.
First, the more recently formed RDPOs were associ-
ated with lower prevalence diseases (p < 0.05). Second,
the younger groups were smaller: they had lower 2012-13
budgets (p < 0.05), fewer members (p < 0.05) and fewer
paid employees (p < .05). Third, the younger groups were
much less likely than the older groups to raise
funds directly from their members and membership
fees (p < 0.01). Fourth, as detailed under Organisa-
tional goals, newer RDPOs placed a higher priority
on research relative to other organisational goals
(p < 0.05).
Formation and governance
More than eighty per cent of the surveyed RDPOs were
founded either by patients with the disease (29 %); par-
ents or other family members (41 %); or both patients
and family members (14 %). Two (3 %) of the 59 leaders
who answered this survey question said their organisa-
tion was founded by researchers or health professionals,
and another seven (12 %) said their RDPO was founded
by patients or families working jointly with researchers
or health professionals. The survey did not provide a
separate response option for patients or family members
who are themselves researchers or health professionals,
but this was the case for at least one RDPO.
While our survey elicited details of RDPO founders
rather than current leaders, as 55 of the 61 respon-
dents identified themselves, we were able to obtain
information about 55 current leaders from organisational
websites. On this basis, we estimated that approximately
three quarters of RDPOs are currently led by volunteers
who are personally affected by the organisation’s focus dis-
ease, either as patients or family members. The remaining
RDPOs – which tend to be larger, older and devoted to
higher prevalence diseases – employ professional adminis-
trators in leadership positions. These organisations had
started as small volunteer groups, and over time evolved
into formal organisations with professional leadership,
paid staff and higher capacity to raise funds.
Size and resources
The surveyed RDPOs varied widely in terms of their
membership numbers, budgets, and staffing; however
most were of modest size. Approximately one third (32 %)
had sixty or fewer members, and more than a quarter
(27 %) had a total budget of $10,000 or less in 2012–13
(see Table 1). As mentioned, only a minority (an estimated
Fig. 1 Age of Australian rare disease patient organisations. The proportion of Australian RDPOs falling into each of six age categories, based on
survey responses from 57 RDPO leaders who provided information about the year in which their organisation was formed
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23 %)3 had paid leaders, and more than half (56 %) had no
paid staff at all.
Most of the wealthier RDPOs were several decades
old and dedicated to higher prevalence rare diseases.
Compared with lower budget organisations, the bigger
budget RDPOs were more likely to receive funding from
community and business sponsors (p < 0.01), philanthropy
groups (p < 0.001), and governments (p < 0.01). On the
whole though, most RDPOs rely heavily on annual mem-
bership fees (usually between $20 and $50 per member),
small donations, the occasional bequest, and “grassroots”
fundraising events (such as fun runs, movie nights, charity
dinners, sausage sizzles and so on). Only about a quarter
of the surveyed RDPOs received government funding
(Table 1). Information on RDPO websites suggested that
government funding comes mainly from small grants
programs for disability self-help groups or – for bigger
RDPOs with professional staff – a funding agreement in
which the RDPO provides allied health, clinical or disabil-
ity support services. The results in Table 1 also show that
twenty per cent of the surveyed RDPOs had received
funding from a pharmaceutical or biotechnology company
in 2012–13.
Goals
Given RDPOs’ historical role as self-help and support
groups, it is notable that 92 % of the surveyed leaders
indicated a goal to “support or promote research”, and
59 % indicated a goal to advocate to authorities about
research-related matters. Nevertheless, most RDPOs also
have goals more traditionally associated with patient
organisations (see Table 2), with 90 % aiming to provide
social support and networking opportunities to mem-
bers, and 97 % aiming to “provide information or educa-
tion to patients and/or their families”. RDPO websites
showed that nearly all leaders compile information about
their RDPO’s focus disease, based on internet sources,
discussions with medical experts, and/or the experiences
of people affected by the disease. In addition to using
their knowledge to educate RDPO members, most leaders
wish to inform the general public (97 %) and health
professionals (82 %) about the disease. RDPO leaders also
use their knowledge in discussions with researchers and in
deciding what research their organisations will fund and
support.
Relative priority of research and other organisational goals
Nine leaders (15 %) identified research as their “top pri-
ority” when asked about the priority of research com-
pared to other organisational goals, and a further five
(8 %) said it was “somewhat more important than other
goals”. Seventeen RDPOs (28 %) had other goals that
were more important than research,4 and the remaining
thirty respondents (49 %) considered research and other
Table 1 Size and resources of surveyed Australian rare disease
patient organisations
Number of RDPOs (per cent
of 61 survey respondents)
Valid
per cent
Geographical coverage
Specific states or territoriesa 19 (31.1) 31.7
Whole of Australiab 30 (49.2) 50.0
Australasian 9 (14.8) 15.0
Australian arm of international
organisation
2 (3.3) 3.3
Not stated 1 (1.6) -
Number of members
60 or fewer 17 (27.9) 32.1
61 – 300 21 (34.4) 39.6
More than 300 15 (24.6) 28.3
Not stated 8 (13.1) -
Number of paid employees
No paid employees 32 (52.5) 56.1
1–2 8 (13.1) 14.0
3–5 6 (9.8) 10.5
6–15 7 (11.4) 12.3
More than 15 4 (6.6) 7.0
Not stated 4 (6.6) -
Total budget in 2012–13
$0 to $10,000 15 (24.6) 27.3
$10,000 to $50,000 9 (14.8) 16.4
$50,000 to $100,000 5 (8.2) 9.1
$100,000 to $200,000 10 (16.4) 18.2
$200,000 to $500,000 5 (8.2) 9.1
$500,000 to $1,000,000 2 (3.3) 3.6
Over $1,000,000 9 (14.8) 16.4
Don’t know/not stated 6 (9.8) -
Sources of funding in 2012–13c
Membership fees 35 (57.4) 58.3
Donations and bequests 48 (78.7) 80.0
Fundraising events 46 (75.4) 76.7
Government 16 (26.2) 26.7
Industry pharma or biotech
company
12 (19.7) 20.0
Philanthropic organisations 19 (31.1) 31.7
Community or business
sponsors
21 (34.4) 35.0
No funding 1 (1.6) 1.7
Funded by founder 2 (3.3) 3.3
Other/don’t know 2 (3.3) 3.3
aIncludes state-based RDPOs of RDPO federations with separate national body
bIncludes national RDPOs with separate state organisations
cTotals exceed 100 % as respondents could choose more than one response.
One respondent did not complete the section on organisational details
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goals to be equally important. Thus, almost three quar-
ters of surveyed leaders felt that their research goals
were at least as important as other goals.
Leaders’ ratings of the relative importance of research
and other organisational goals were significantly nega-
tively correlated with the age of the organisation: that is,
leaders of newer groups considered research a higher
priority than did leaders of older RDPOs. This result
was observed even though older, more established orga-
nisations had significantly bigger budgets and were more
likely to have funded research in the last five years.
Many older RDPOs have broadened their original goals
to include research, but our data suggest that there has
also been a concurrent formation of new “research-
focused” RDPOs. Based on their recent review of litera-
ture on patient organisations’ involvement in “genomic
science”, Koay and Sharp predict that the trend towards
the increasing formation of research-engaged patient orga-
nisations will continue and strengthen in future years [11].
While our sample size was not large enough to allow
us to statistically validate “types” of RDPOs, we did
observe differences between leaders according to their
depth of interest in research. Based on their websites,
survey comments, and (in two cases) interview data,
the nine survey participants who rated research as
their top priority appeared driven by a personal ambi-
tion to contribute to advances in treating diseases
that had strongly affected their own lives, either as
patients (three cases), parents of a living or recently
deceased child (five cases) or a close friend (one case)
of someone with the disease. In eight out of the nine
cases, the diseases were degenerative conditions not
apparent at birth: the RPDO leaders believed these
diseases to be potentially curable but neglected by the
research establishment. These leaders tended to be
very proactive in trying to initiate new research and
in developing relationships with researchers. Seven of
these nine RDPOs had been established with the primary
or exclusive purpose of advancing research, and some of
the leaders appeared to have little interaction with other
members of the patient community.
Compared with the RDPOs that gave greater priority
to research, RDPOs with equal interest in research and
other goals tended to be older and to have larger mem-
berships. They had usually started as patient support
groups but had become involved in research as their
resources grew, scientific knowledge advanced and/or
opportunities for participation presented. Unlike the
leaders of highly research-focused groups, leaders with
“balanced goals” wished to support research but did not
necessarily regard their RDPOs as being responsible for
initiating new programs of work or changing research
agendas. They also tended to see their research and
patient support goals as intertwined, with several com-
menting that research involvement brought hope to their
members and strengthened ties between them.
RDPOs with the least interest in research were typic-
ally small support groups, some of which were devoted
to conditions – such as spontaneous congenital malfor-
mations – for which there appear to be little likelihood
of cures in the foreseeable future. The research involve-
ment of these organisations, if any, tended to be driven
by researchers (for example, responding to researchers’
request to advertise their studies on RDPO websites)
or raising small amounts of money for a particular
hospital or other institution with which they have a
close relationship.
Research activities
Overall, 95 % of the surveyed RDPOs had undertaken
at least one research-related activity, as listed in Table 3,
in the last five years.
Table 2 Goals of RDPOs
Goala Number of RDPOs (per cent of
61 survey respondents)b
To raise community awareness and knowledge of the disease 59 (96.7)
To provide information or education to patients and/or their families 59 (96.7)
To provide information or education to health professionals 50 (82.0)
To provide social support or networking opportunities for patients and/or their families 55 (90.2)
To provide services (for example, respite care), financial assistance, or other resources
(for example, equipment) to patients and/or their families
25 (41.0)
To support or promote research on the disease 56 (91.8)
To advocate to government or other authorities for research funding, other research
resources, or changes in regulations relating to research
36 (59.0)
To advocate to government or other authorities on other matters
(for example, access to services or existing therapies)
41 (67.2)
aThe code set for this question was based on the website review, which revealed that RDPOs’ statements of goals (or missions, priorities and so on) could be
categorised according to the eight statements listed in the table
bTotals equal more than 100 % because respondents could choose more than answer
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Research funding
Fifty-nine per cent of the surveyed RDPOs had provided
funds for research in the last five years (Table 3). Austra-
lian RDPOs generally do not provide large sums of
money relative to the high costs of conducting scientific
and medical studies. Except for one organisation that
gave more than $1,000,000, no RDPO allocated more
than $500,000 to research in the 2012–13 financial year.
A chi-square test of the relationship between categories
for “total budget” and “research expenditure” showed
that RDPOs’ research funding was strongly related to
their total budgets (p < 0.01). This was not a perfect
relationship, however, one RDPO with an annual
budget of more than $1 million allocated less than
$10,000 to research in 2012–13. In contrast, two
interviewed RDPO leaders said they dedicate “every
cent” of their funds to research.
In accordance with previous findings that RDPOs are
increasingly using their financial leverage to commission
research projects favoured by patient communities ra-
ther than determined by researchers [10, 13], many of
the leaders we interviewed had initiated and funded
research projects with the explicit aim of encouraging
researchers to study matters identified as priorities by
the RDPO.
Non-financial support to researchers
Approximately three quarters of the RDPOs (77 %) had
provided non-financial support for research in the five
years prior to the survey. Answers to a follow-up ques-
tion about the types of non-financial support provided
revealed that thirty-four RDPOs (56 %) had helped to
identify potential participants for clinical trials or stud-
ies, and 28 (46 %) had helped recruit respondents for
surveys. These activities may occur in the context of
studies RDPOs have funded and/or at the request of
researchers.
The support provided by some RDPOs extends beyond
“helper” roles to proactive facilitation of connections
between researchers working in different research in-
stitutions and/or disciplines. Several study participants
noted that collaboration between researchers is particu-
larly important for rare disease research, which often
requires co-operation between different institutes to en-
sure sufficient numbers of patients or biospecimens. Some
leaders expressed strong sentiments about their organiza-
tion’s role in bringing researchers together. For example:
We formed a collaborative of international and
Australian institutions…If you’re playing football, it’s a
lot easier to pass the ball to someone else to get to the
goal line quicker. So we’re embracing the collaborative
aspects. We’re big on working with people.
– Paul, interviewed RDPO leader
Other RDPO leaders encouraged connections between
researchers in more subtle ways; for example, by keeping
researchers informed of each other’s work or organising
meetings allowing them to share information directly
with each other. Overall, 14 (30 %) of the surveyed RDPOs
that had provided research funding or non-financial sup-
port agreed that they “had undertaken actions aimed at
creating closer links between different researchers”.
Patient registries and biobanks
Twenty five (41 %) of the surveyed RDPOs had contrib-
uted to a patient registry or biobank established by a
research institution. The survey did not obtain details
about the nature of these contributions, but website
Table 3 Research-related activities undertaken by RDPOs in the last five years
Activity Number of RDPOs (percent of
61 survey respondents)a
Provided funding to researchers, research bodies or a specific research fund/foundation separate to the RDPO 36 (59.0)
Collaborated with or provided non-financial support to researchers or research bodies 47 (77.0)
Established or maintained the organisation’s own patient registry (i.e. a data set containing clinical information
about patients) or biobank (collection of biological samples)
7 (11.5)
Contributed to an external patient registry, data set, or biobank 25 (41.0)
Advocated to government or other authorities for research funding, other research resources, or changes in
regulations relating to research
22 (36.1)
Participated in a committee within a government or research body responsible for research decision-making 12 (19.7)
Provided information or counselling to assist participants in research studies 21 (34.4)
Disseminated information about research (for example, by making information about research findings available
on your website)
48 (78.7)
Conducted the organisation’s own research 16 (26.2)
None of the above 3 (4.9)
aTotals equal more than 100 % because respondents could choose more than answer
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content and comments made by study participants indi-
cated that RDPOs may support registries and biobanks
financially; by advising on their design or evaluation; or
by encouraging patients and families to contribute their
data and/or their biospecimens (usually via a treating
clinician).
In addition to the RDPOs that contributed to researchers’
registries or biobanks, seven RDPOs (11 %) had managed
their own patient registries in the last five years. Inter-
nationally, RDPOs are increasingly establishing their own
registries and biobanks to facilitate research on their dis-
eases [56–58]. However, given that establishing and main-
taining registries and biobanks is complex and resource
intensive, this trend has led to concerns about quality assur-
ance and ethical oversight of RDPO-managed collections of
patient data and biospecimens [58, 59].
Research-related lobbying
The data in Table 3 show that RDPOs privilege more
direct forms of involvement in research over lobbying
activities. Only 36 % of RDPO leaders reporting having
“advocated to government or other authorities for re-
search funding, other research resources, or changes in
regulations relating to research” in the last five years.
Supporting claims by previous authors that disease-
specific RDPOs prioritise direct engagements with re-
searchers because they lack the organisational capacity
and numbers required for successful lobbying of author-
ities [9, 60], we found that RDPOs with higher annual
budgets and numbers of paid staff were significantly
more likely to undertake lobbing activities (p < 0.05).
Participation in research committees
Only twenty per cent of the surveyed RDPO leaders
had participated in committees established by govern-
ment or research bodies responsible for research decision-
making. Further highlighting the importance of RDPOs’
financial resources in terms of opportunities to influ-
ence research, we found a strongly significant association
between RDPOs’ annual budget and their participation in
research decision-making committees: wealthier organisa-
tions were much more like to have these opportunities
(p < 0.01).
Providing information or counselling for research
participants
Some Australian RDPO leaders have developed a sophis-
ticated understanding of research governance and use
this knowledge to advise members of their rights as study
participants and the risks and benefits of their participa-
tion. About a third of the surveyed leaders (34.4) had
“provided information or counselling to assist participants
in research studies” (Table 3).
Disseminating research information
Disseminating research information, which had been
done by 79 % of Australian RDPOs (Table 3), is an
important form of engagement with research. Many
RDPO websites showed that leaders had compiled in-
formation about current research projects and findings.
Interviewed leaders gave examples of how this informa-
tion had led organisational members to develop ideas for
further research, which they then used in discussions with
researchers or as a basis for awarding research funding.
Studies conducted by RDPOs
Sixteen (26 %) of those surveyed indicated that their
RDPO had initiated and carried out their own research
in the last five years. RDPOs’ research projects were
usually led by volunteers associated with the organisa-
tion. However, in three cases the research was conducted
by professionals employed or contracted by RDPOs.
Leaders’ explanations of why their RDPO conducted
its own research revealed two main themes: first, an
inability to attract professional researchers to conduct
research on the disease and, second, a perceived need
for more information about the psychosocial impacts of
the disease. Examining RDPOs’ independent research in
the context of other activities reported in the survey and
on their websites, it appeared that their studies were
usually conducted in the hope that their findings would
influence professional researchers, clinicians or policy
makers. Five of the 16 respondents made this motivation
explicit in their comments.
While some commentators claim that patient organisa-
tions are increasingly conducting their own evaluations
of therapies they believe could help treat their disease
[61–64], we found no evidence that Australian RDPOs
had organised interventional clinical studies independ-
ently of the research establishment. However, more
than a third (38 %) of the surveyed leaders were aware
of members of their organisation who had participated
in “participant-led” clinical studies (for example, drug
tests conducted by groups of people who connect on-
line) independently of both the RDPO and biomedical
researchers.
Perceived challenges
Key challenges identified by our study participants are
discussed below.
Lack of RDPO resources and expertise
Insufficient funding and consequent limitations of organ-
isational capacity were the factors most frequently cited
by surveyed respondents when asked to explain why their
organisations had not been involved in research in the
way they would wish. This was also a prominent theme in
interviews with RDPO leaders.
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Although the leaders who participated in the survey
and interviews believed their own research funding was
well managed, several suggested that “other” RDPO
leaders lack the expertise needed to direct their organi-
sation’s research funding in ways most likely to have the
desired impact. This is because RDPO leaders are
(usually) non-scientists, often with little experience of
financial or contractual governance, who may struggle to
identify research projects and funding strategies that
make best use of their resources. A number of study
participants expressed concerns that RDPO leaders may
not obtain informed and impartial advice on the re-
search they plan to fund. Although about 80 % of the
“research funder” RDPOs indicated they have scientific
or medical advisors, these same advisors may be po-
tential recipients of the RDPO’s funds. The difficulty
of obtaining impartial expert advice was noted by a
survey respondent:
It is very important to seek independent advice from
one's SAC [scientific advisory committee] and to have
a SAC comprising of experts of the best disease
reputation and integrity. Finding world renowned
advisors in whom you have faith would recommend
the best project [even if it was] competing against one
from their own lab is harder than you think and it
takes a lot of critical information and knowledge and
networking to acquire this confidence.
– Survey respondent
The research environment
Comments about RDPOs’ limited resources and expert-
ise comprised about two thirds of survey respondents’
answers to the open-ended question on factors prevent-
ing them from being involved in research in the way
they would wish. However, a third of the comments
referenced aspects of the external environment. Several
respondents claimed that there were no or few Australian
researchers “interested” in their diseases – although it was
not clear if they attributed this to lack of funding or
researchers’ unwillingness to study rare diseases. Other
respondents commented explicitly that rare diseases are
neglected in Australian government research funding
allocations, relative to their prevalence in the population
and the impact on individuals and society.5 A few attrib-
uted this to the government’s strong focus on Australia’s
national health priorities, which are common diseases
[65]. Several respondents also commented that research
on their diseases was impeded by the lack of a mech-
anism for collecting patients’ demographic and clinical
data: these respondents called for the development of an
Australian rare disease patient registry, as exists in the
United States [56] and many European countries [66].
While survey respondents were, overall, more satisfied
than dissatisfied with the “extent to which researchers
listen to advice and input from the RDPO” (their average
rating of 3.6 out of 5 indicated a position somewhere be-
tween “neither satisfied nor dissatisfied” and “satisfied”),
several respondents stated that attitudes and practices
within the research community – specifically, researchers
unwillingness to work collaboratively with patient organi-
sations or take account of their ideas – was a barrier to
the RDPO’s involvement. For example:
Walking the walk is not our problem but being
volunteers is perceived by some as incongruous with
having skill, expertise and deep knowledge.
– Survey respondent
There is no collaboration between our organisation
and the researchers about possible opportunities for
patient family members to contribute or requests for
involvement apart from the provision of funding.
– Survey respondent
However, while some participants in our study were
critical of researchers’ perceived reluctance to involve
RDPOs in their work, others recognised the challenges
of incorporating lay perspectives into scientific studies.
According to a key informant, the effectiveness of in-
volving RDPOs in research decision-making and de-
liberative processes may be limited by representatives’
lack of preparation for these roles:
I know from the projects that we’re involved in…there’s
a big emphasis on having patients involved in the
planning and the setup of these research projects. But
the extent to which they have the knowledge and the
training that might be necessary for them to make an
informed [contribution]…I mean that sounds
paternalistic but, you know, to be able to contribute in
a way that’s in their best interest, I’m not sure how
much training they’re getting prior to being asked to
participate as a representative for a patient
organisation.
– Melanie, key informant
Discussion
Despite differences in their respective research environ-
ments, comparison of our survey data with available data
from Europe and the US suggests that Australian RDPOs
are similar to their international counterparts and engage
in relationships with researchers in broadly the same ways.
Importantly, surveys in Europe and the US, respectively,
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show that most RDPOs in those jurisdictions are also
small, low-budget organisations led by volunteers [35, 67].
There are, however, some specific differences between
our findings and results of a survey of European RDPOs
conducted by EURORDIS in 2009 [34, 67]. First, the
59 % of Australian RDPOs that had provided funds for
research in the five years before our survey is notably
higher than the 37 % of European RDPOs reported to
have funded research in the five years prior to the
EURORDIS survey [34]. Second, while only 20 % of our
surveyed leaders agreed that they had “participated in a
committee within a government or research body respon-
sible for research decision-making”, 30 % of European
RDPO leaders answered affirmatively when asked a more
limited survey question about “participation in scientific
committees within institutions” [67]. Third, compared
with the 49 % of European RDPOs reported to have
provided information for “clinical trial participants” in the
five years prior to the EURORDIS survey, only 34 % of
Australian RDPOs had provided information for partici-
pants in any form of research.
These differences may reflect better funding of rare
disease research and greater opportunities for patient
participation in deliberative processes in Europe, and the
influence of organisations such as EURORDIS in helping
RDPOs to support research participants and patient
advocates. European RDPO leaders may feel greater
confidence that research will progress without their
financial assistance and may channel their desire to
support research in other ways. Noting that our survey
was conducted four years after the EURORDIS survey,
recent developments further supporting European rare
disease research [68] and RDPOs’ research involvement
[23] may have accentuated the differences we observed.
Contributions and constraints associated with RDPOs’
research involvement
Compared with previous surveys, our study’s inclusion
of in-depth interviews and website review allowed for a
richer understanding of the experiences and views of
RDPO leaders. Given that most RDPO leaders in our
study reported significant challenges in meeting their
research aspirations – which they usually attributed to
the organisation’s small size and resources – we believe
that the focus in academic and popular literature on
RDPO “success stories” may have diverted attention
from the struggles and challenges experienced by the
majority of RDPOs when trying to influence research.
We contend that the types of organisations highlighted
in the literature – such as those led by highly driven
individuals with significant business and entrepreneurial
skills [10, 15, 21, 69]; large professionalised organisations
with significant financial clout [70–72]; and political
activists [73] – constitute only a minority of RDPOs.
Consistent with popular narratives of RDPOs’ impact on
research, a few Australian RDPOs have helped achieve
significant scientific and therapeutic advances. For ex-
ample, Muscular Dystrophy Western Australia is recog-
nised as a major financial contributor to ground-breaking
therapy development conducted at the Australian Neuro-
muscular Research Institute [74]. The leader of another
Australian RDPO, Mission Massimo [75], has spearheaded
important discoveries through initially conducting desktop
research and then recruiting scientists to further investi-
gate his ideas.
While in most cases the outcomes to date of RDPOs’
involvement are less dramatic, it is clear that patient
organisations contribute in a variety of ways to rare
disease research, and not merely through fundraising. By
establishing networks of patients and their families nation-
ally or even internationally, RDPOs have contact with
dozens or even hundreds of individuals affected by a rare
disease and they can therefore help researchers overcome
the difficulty and high cost of accessing study participants,
patient data and biological specimens. RDPO leaders may
propose novel ideas for research, based on the experiential
expertise of patients and families, their reading of relevant
biomedical literature and – in some cases – research
conducted by the RDPO itself. Many leaders also act as
research “intermediaries” [76], taking an active role in
forging connections between researchers in different areas
and institutions. Such connections are increasingly recog-
nised as being critical to the future of rare disease research
and biomedicine generally, particularly the translation of
scientific discoveries to clinical therapies [77–79].
As well as contributing funding, logistic support and
expertise – which may facilitate scientific advances – a
second important role of RDPOs is to help align the
work of researchers and policy-makers with the needs
of the public. This is an explicit aim of the current
Australian Government [80]. Similar to many other
developed nations [81–83], the Government has policies
encouraging publicly funded researchers to involve pa-
tient/consumer representatives in their work [84, 85].
Such policies are based on the belief that there is ethical
value in ensuring patients’ voices are heard [11] and that
their participation will provide “real world” information
about health conditions and the impacts of research prac-
tices on patient communities [86, 87]. Despite the exist-
ence of “consumer involvement” policies, however, only a
minority of Australian RDPOs have the opportunity to be
involved in the formal decision-making processes of
researchers and policy-makers.
A third way in which RDPOs contribute to research
is by empowering research participants and thus help-
ing to uphold established standards of ethical research
conduct. As trusted sources of information for people
affected by rare diseases, RDPOs can help to protect
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and support patients and family members who take
part in research studies. Not only do some leaders educate
their members about their rights and the potential risks
and benefits of their participation in studies, but they may
also provide information aimed at helping patients and
families to be more sophisticated consumers of informa-
tion provided by researchers, the media, and marketers of
therapies. While responsibility for research integrity ultim-
ately rests with researchers and policy-makers, the role
played by patient organisations is recognised internation-
ally by bioethicists [86, 88].
Despite the value of their involvement in research, how-
ever, RDPO leaders identify considerable challenges asso-
ciated with their research goals. As mentioned, leaders
themselves explain these challenges mainly in terms of
lack of resources, but we believe two underlying factors
may contribute to their difficulties: a growing number of
small, uncoordinated RDPOs and lack of policy support in
Australia for rare disease research and patient advocacy.
RDPO proliferation and fragmentation
In accordance with evidence from the US that the num-
ber of disease-specific non-profit organisations has been
rising sharply since the 1990s [89], it appears that new
RDPOs are being formed at a greater rate than in the
past. A key informant to our study said that this growth
has been driven by the internet (which enables RDPOs
to form around even extremely low prevalence diseases)
and new knowledge about the genetic underpinnings of
diseases (which has resulted in some RDPOs splintering
into groups devoted to specific forms of related diseases).
These observations are supported by our survey data
showing that RDPOs formed in the last decade focus on
lower prevalence rare diseases and have lower member-
ship numbers than older groups. Given our survey data
showing that RDPOs’ opportunities to be involved in re-
search (either financially or in other ways) are related to
their size and resources, it is likely many of these
smaller RDPOs will struggle to achieve their research
goals. This was suggested by an interview participant.
My experience is that there are many [RDPOs]
that overlap, that do the same thing: you’ve got
quadrupling or tenfold…of administrative costs.
Running a non-profit is not a trivial exercise…the
workload is immense…If you’re going to have all these
fundraising dinners to feel good about it, and I hate to
sound harsh in saying this, but if you’re going to raise
a thousand dollars at the end of twelve months effort
that’s taken ten thousand hours of work, you’re better
off to go get an extra job, make a thousand dollars
and donate it to another charity.
– David, interviewed RDPO leader
As well as reducing the ability of individual RDPOs to
attract funds from affected individuals and the public,
the growth and fragmentation of RDPOs may mean that
they neglect opportunities for collaboration. While we
found little evidence that different RDPOs had collabo-
rated for research purposes, it has been suggested that
joint studies funded by patient organisations working in
the same or similar disease areas (for example, different
diseases causing epilepsy or different blood disorders)
would provide economies of scale and might also identify
common disease pathways and drug targets [4]. RDPOs’
focus on their own specific diseases may also compromise
their involvement in collaborative efforts to influence
government policy on matters of common concern – such
as funding for rare disease research infrastructure and
regulations relating to genetic testing, and therapy devel-
opment, approval and subsidisation.
Lack of supporting policies and programs in Australia
Australian RDPOs currently rely mainly on their own
expertise and resources when trying to advance research,
as there is no policy framework to help them develop
mutually beneficial relationships with researchers. In
contrast, European patient organisations are actively
engaged in RD-Connect, a EU-funded initiative linking
rare disease registries, biobanks and other databases [28]
and in the development of outcome measures for clinical
trials, therapy approval, and post-marketing drug surveil-
lance [23, 49]. In the US, each of the research consortia in
the National Institutes of Health’s Rare Diseases Clinical
Research Network program directly involves patient
organisations as well as researchers – enabling scien-
tists, clinicians and people affected by rare diseases to
work together on disease-specific projects [50]. US exam-
ples also include the Patient-Centred Outcomes Research
Institute [90]: this is not specific to rare diseases, but the
Institute’s Advisory Panel on Rare Diseases provides guid-
ance on how to foster collaborative approaches between
researchers and RDPOs [14].
For RDPOs without the capacity to raise substantial
funds for research, opportunities to be involved in re-
search depend on the level of research activity funded by
government and industry. In Australia, the ability of
RDPOs to contribute to research is therefore constrained
by the fact that the research environment provides
few incentives for researchers to study rare diseases
(see Background section).
Opportunities to strengthen RDPOs’ involvement in
research
Our study was not designed to develop or evaluate
policies: however, its findings do highlight opportun-
ities to strengthen RDPOs’ involvement in research,
and enhance the value of this involvement for both
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researchers and RDPOs. We outline some preliminary
suggestions below for further investigation and discus-
sion with stakeholders.
National leadership in rare disease policy and planning
There has been significant government leadership in the
development of rare diseases national plans in other ju-
risdictions, particularly in Europe [25]. The plans pro-
vide a framework for coordination and monitoring of
the scarce resources associated with various rare dis-
eases, with the aim of creating new opportunities for re-
search, service provision and patient group engagement.
An Australian National Rare Disease Plan could address
some of the issues highlighted by our findings, such as
lack of data on rare disease research projects and fund-
ing; fragmentation of resources for rare disease research;
lack of opportunities for patient organisations to be
involved in research unless they have significant
funds; and a perceived lack of fairness in the alloca-
tion of Government research funding.
To date, however, calls by the Western Australian
State Government [38, 40], researchers [39, 91], medical
professionals [92] and an Australian rare disease advo-
cacy group [52] for a nationally coordinated approach
to rare disease planning have gone unheeded. We rec-
ommend that the Australian Government should work
with rare disease advocates, researchers and other stake-
holders towards the development and implementation of
a national plan for rare diseases.
Support for collaboration between researchers and patient
organisations
As the main Australian Government agency responsible
for biomedical research policy and funding, the National
Health and Medical Research Council (NHMRC) would
be well placed to take the lead in connecting patient
organisations and researchers, and developing resources
to help them work together. A participant in our study
suggested that NHMRC could extend its existing initia-
tive, negotiated by a small group of RDPOs, in which
RDPOs are advised of relevant, high-quality research
applications that the NHMRC is unable to fund. By
arrangement with the NHMRC, RDPOs could also ask
researchers applying for their funding to first submit
their proposals to the NHMRC. This would enable pa-
tient organisations to access expert, independent advice
and to direct their funds to studies that have scientific
merit and value for the patient community.
Infrastructure for rare disease research
As suggested by some of our study participants, the
environment for rare disease research in Australia
would be greatly improved by a nationally coordi-
nated approach to rare disease research infrastructure,
in particular through establishment of patient registries
and biobanks. Well-recognised problems relating to rare
disease registry in Australia include duplication of effort
and poor economies of scale in disease-specific registries;
lack of consistent standards and comparability of informa-
tion across different registries; a lack of registries for
many rare disease communities; the short-term nature
of registries created for specific research projects; and
perceived inadequacies in patient/parent input to the
design of some registries [93]. Similar to registries,
biobanks for rare diseases are fragmented and lacking
either inter-operability or consistent standards for speci-
men collection, storage, obtaining patient/parent consent,
or sharing of samples between researchers [46].
An internet tool developed by Western Australian
researchers presents a specific opportunity to develop an
Australian rare disease registry [93]. Importantly, this
registry architecture is open source – meaning that it is
freely available for use or modification – and allows
customised data input by patients or their family mem-
bers. Therefore it could provide a secure, presumably
low-cost, alternative to RDPO-managed registries and a
basis for collaborative data collection by researchers and
patient organisations. These features of the registry may
lead to greater levels of data capture, which is critical in
advancing knowledge about rare diseases. Further, a
national registry would help the Australian research
community to align itself with efforts in Europe and the
US to “internationalise” rare disease research by foster-
ing research collaborations [94] and connectivity be-
tween national and trans-national rare disease registries
and biobanks [95].
RDPO coordination and support
Better coordination of rare disease patient advocacy and
patient groups in Australia was described as “long over-
due” in 2006 [92], but it was only in 2012 that a small
national advocacy group, Rare Voices Australia, was
formed. Rare Voices Australia, which currently relies
mainly on funding from pharmaceutical companies, has
focused on consultation and lobbying on issues of rele-
vance to rare diseases, particularly the development of a
national plan and patients’ access to high-cost therapies
[52]. However, some resources for RDPOs wishing to
engage in research are available from peak agencies
for “genetic” and rare disease groups in three states
(Victoria, New South Wales and Western Australia),
which were established by state government health
departments in the 1980s and 1990s.
In our view, an important aspect of the proposed
National Rare Disease Plan would be to articulate the
respective roles of Australia’s national and state-based
rare disease alliances. These organisations should work to-
gether to ensure optimal use of their collective resources.
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Our study findings point to several ways in which rare
disease alliances could support the research aspirations
and activities of disease-specific patient organisations:
first, by providing guidance for RDPOs that fund or other-
wise engage in research; second, by engaging with RDPOs
in order to reflect all points of view in research-related
advocacy; third, by helping RDPOs to safeguard the
welfare of their members who participate as “subjects” in
traditional and “participant-led” research; and, fourth, by
promoting collaboration between RDPOs, including col-
laboration on joint research initiatives. The Australian
Government should give consideration to appropriate
funding models and levels to enable the national and
state-based alliances to carry out these roles without
undue reliance on the pharmaceutical industry.
Conclusions
In this article, we have explored the research-related
goals, activities and challenges of a sizable group of
Australian RDPO leaders. Although a number of other
countries have better-developed policies and programs
supporting RDPOs’ involvement in research, many of the
issues we identify in this Australian sample of RDPOs are
likely to be applicable to RDPOs in other parts of the
developed world.
In the context of scarce government and industry
funding for rare disease research, the funds and logistical
assistance provided by RDPOs may significantly advance
research. Beyond their material and practical contri-
butions, RDPO leaders and their members possess
knowledge that can enrich research and better align
its directions and practices with the needs of people
affected by rare diseases. Despite the value of their
involvement, however, RDPOs face significant challenges
in achieving their research goals. Most leaders focus on
fund-raising, expertise and resourcing issues when explain-
ing their difficulties, but it is clear that their problems
are exacerbated by the fragmentation of the RDPO
sector and the marginalisation of rare diseases in
health and research policy.
We have suggested that there are considerable oppor-
tunities in Australia, building on the findings of this
study and work conducted internationally, to strengthen
and safeguard RDPOs’ involvement in research. Such
initiatives – ideally implemented as part of a nationally
coordinated and government-supported plan to improve
rare disease research, services and patient advocacy in
Australia – could help advance scientific knowledge and
therapy development, thereby alleviating the personal
and societal burdens of rare diseases.
Endnotes
1While the Australian Therapeutic Goods Authority
considers a rare disease to be a condition, syndrome or
disorder that affects 1 in 10,000 people or less, there
is a strong push from Australian rare disease advo-
cates for a nationally consistent definition aligned
with the European Union (EU) definition, which re-
fers to an estimated prevalence of less than 5 in
10,000 (1 in 2000). Our study uses the EU definition.
2Because six survey respondents chose not to identify
themselves, there was a small chance that an RDPO
classified as a “non-responder” had in fact participated
in the survey.
3Estimate based on website information. The survey
asked about the number of paid staff, but did not dis-
tinguish between paid leaders and paid staff perform-
ing other roles (for example, such administration or
fundraising). The estimate includes survey respondents
from separate state branches of large federated RDPOs,
with paid leaders in each state as well as a paid national
leader.
4Including the four respondents who had no research
or research advocacy goals, and who were therefore not
asked the question.
5It is not possible to check the accuracy of participants’
perception that rare diseases as a group are under-funded
in Australian research expenditure, as the Government’s
main research funding body, the National Health and
Medical Research Council, does not provide data on
allocations to rare disease research.
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